Scientists Find New Uses for Old Drugs

December 16, 2013Media coverage

Interview Of Biovista’s President Aris Persidis in Voice Of America by Jessica Berman; Monday, December 10, 2013   Here is an excerpt… “It is a very easy way to explore whether something that is therapeutically beneficial in one area and for one type of patient might be useful for another type of patient,” said Aris … Read More

GEN: Seasoned Drugs Offer Therapeutic Gold Mine

May 23, 2013Media coverage

Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More

VA BIOTECH – Concept to Commercialization

April 11, 2013Events

Biovista announces that its President, Dr. Aris Persidis, will participate in the “VA BIOTECH – Concept to Commercialization” Facebook event. About VA BIOTECH – Concept to Commercialization event: Charlottesville is home to some of the most cutting edge biotechnology firms in the Country. This panel, presented in partnership with U.Va. Innovation and Charlottesville Business Innovation … Read More

Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

March 26, 2013Press Releases

CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More